youtube.com· NEJM Group · YouTube·· 8 hours agoPickScore56
Medical Marijuana Rescheduled from Schedule I to Schedule III, Research Rules Eased but Funding Remains a Bottleneck
In brief
In April 2026, under a December 2025 executive order, the Trump administration rescheduled medical marijuana and future FDA-approved cannabis products from Schedule I to Schedule III. A 2023 HHS review found credible scientific support for cannabis in pain, anorexia, and nausea and vomiting, but mixed evidence for chronic pain. Before rescheduling, the United States already had more than 33,000 prescribers and 41 states allowing medical marijuana.
Why it matters
It compares registration and regulatory changes after rescheduling and notes that mixed evidence and insufficient funding still limit further research.
